Molecular Diagnostic Market

Molecular Diagnostic Market Analysis - Forecasts to 2025 By Product (Instruments, Reagents, Others), By Technology (PCR, Hybridization, DNA Sequencing, Microarray, INAAT, Mass Spectrometry, Transcription Mediated Amplification), By Application (Infectious Disease, Oncology, Genetic Tests, Pharmacogenomics, Neurological Diseases, Cardiovascular Diseases Microbiology), By End-user (Hospital, Laboratories, Others), By Region (North America, Europe, Asia-Pacific, Middle East & Africa, Central & South America), End-use Landscape, Vendor Landscape, and Competitor Analysis | Business Intelligence Report - Global Market Estimates

Category Healthcare

Format

This report was recently updated on April 11 2024 with the latest and most recent market numbers

Molecular Diagnostic Market Insights

The worldwide molecular diagnostic market is anticipated to grow at a CAGR of more than 9% from 2017 to 2025. High prevalence of infectious diseases, cancer; increasing awareness & acceptance of personalized medicines, development of biomarkers; & advancements in molecular and genomics technology research are expected to boost growth of the industry.

However, increased cost of molecular diagnostics tools, dearth of skilled labour to handle new & complex platforms, coupled with complex regulatory frameworks are the major factors that are anticipated to hamper industry growth.

Taking this into consideration, expanded cost of molecular diagnostics apparatuses, and lack of skilled labour to deal with new and complex procedures, along with the complicated administrative structure are the central factors expected to restrain industry growth.

Product Type Insights

The molecular diagnostic market is divided into instruments, reagents & kits, services, software and programming. The reagents & kits segment is expected to represent the largest share in the market over the forecast period. The instruments segment is also anticipated to observe high growth rate on account of expanding R&D activities in the biomarker industry.

Technology Insights

PCR is anticipated to command the largest share in 2016 and microarray segment is projected to grow at a high CAGR over the coming years. Factors such as the expanding demand for atomic-targeted drugs/treatment (customized medicine) are anticipated to drive the microarray market amid the projected time frame.

Mechanical headways play a vital role in conveying fast and accurate test outcomes. This is evaluated to enable greater penetration of sub-atomic or molecular diagnostics in care (PoC) facilities and healing centres.

The DNA sequencing fragment is expected to witness lucrative development with a CAGR of around 16% from 2017 to 2025. Key factors contributing to the development of DNA sequencing are availability of technologically advanced products with high accuracy, speed, and high throughput screening.

Application Insights

It has been predicted that infectious diseases segment will hold the largest share of the global market in 2016, ensued by the blood screening and oncology segments.

Polymerase Chain Reaction (PCR) is incorporated among specialists, researchers, and social insurance experts to determine variations that underlie hereditary diseases.

Oncology studies utilize MDfor screening, treatment selection, detection, and relapse monitoring of cancer. The current demand for malignancy research treatment in complex molecular tumour diagnostics is very high.

The hereditary examination of samples using next-generation sequencing technologies enables analysts to distinguish hereditary changes and patterns in tumour tissues, thereby helping doctors to determine the most effective options for treatment.

Regional Insights

Established laboratory accreditation framework, positive awareness programs for educating patients about early diagnosis, and the rising expenditures of medical services are the main factors fortifying the dominance of the market in North America.

The Asia-Pacific region is expected to develop at the highest CAGR during the projected time frame. The extent of development in this region can be attributed to the existence of high-growth markets such as China, India, and South Korea.

Also, growing external funding for clinical studies in China and India is anticipated to drive developments in the industry.

End - Use Landscape

The end-use landscape entails a list of current and prospective consumers prevailing across the regions. This section provides company addresses, contact details, products, and regional presence of companies who are purchasing or are likely to purchase products from the global molecular diagnostic market over the coming years. The application is mostly used in Hospitals, Laboratories, and Clinics. Some leading purchasers of the market are University of Texas MD Anderson Cancer Centre, Memorial Sloan Kettering Cancer Centre, and Mayo Clinic.

Competitor Analysis

The expanding rate of infectious & fatal diseases, hereditary issues, phenomenal prospects in the field of pharmacogenetics, and the expanding demand for PoC diagnostics is projected to augment sub-atomic diagnostics market growth.

In February 2016, Roche Molecular Diagnostics launched cobas 4800 system which helps in sample preparation using PCR technology for detection and amplification. Already established players are undertaking R&D endeavours to create novel biomarker-based partner diagnostic tests.

F. Hoffmann-La Roche Ltd, Abbott, and bioMérieux SA got the U.S. FDA endorsement for partner diagnostics for cancer therapeutics in 2014. For instance, in the U.S., the introduction of Clinical Laboratory Improvement Amendments certification has prompted utilization rate of PoC devices.

Due to greater and prominent opportunities in both developed and developing nations, organizations are undertaking key initiatives, such as, mergers & acquisitions, new product advancement, and funding ventures to enhance market presence.

1 RESEARCH METHODOLOGY

1.1 DESK RESEARCH
1.2 PRIMARY RESEARCH
1.3 ANALYSIS AND OUTPUT
1.4 FINAL OUTPUT FROM DESK AND PRIMARY RESEARCH

2 ECOSYSTEM OVERVIEW

3 TECHNOLOGICAL TRENDS IN MOLECULAR DIAGNOSTIC MARKET

4 DEMAND AND SUPPLY MATRIX

4.1 INTRODUCTION
4.2 DEMAND SIDE ANALYSIS
4.2.1 MOLECULAR DIAGNOSTIC MARKET DRIVERS
4.2.2 MOLECULAR DIAGNOSTIC MARKET RESTRAINTS
4.2.3 MOLECULAR DIAGNOSTIC MARKET OPPORTUNITIES
4.2.4 MOLECULAR DIAGNOSTIC MARKET CHALLENGES
4.3 SUPPLY SIDE ANALYSIS
4.3.1 FUTURE SCENARIO (CAGR% VS. COUNTRY)
4.3.2 MAPPING KEY MOLECULAR DIAGNOSTIC MANUFACTURERS
4.3.3 PORTER’S FIVE FORCES ANALYSIS
4.3.3.1 Threat of new entrants
4.3.3.2 Threat of substitutes
4.3.3.3 Bargaining power of buyers
4.3.3.4 Bargaining power of suppliers
4.3.3.5 Intensity of competitive rivalry
4.3.4 MOLECULAR DIAGNOSTIC MARKET: TREND ANALYSIS
4.4 PESTLE ANALYSIS
4.5 IMPACT ANALYSIS
4.6 PATENT LISTING
4.7 BEHAVIOURAL ANALYSIS
4.7.1 KEY MACRO INDICATORS
4.7.2 KEY MICRO INDICATORS

5 REGULATORY FRAMEWORK

6 MOLECULAR DIAGNOSTIC MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 INSTRUMENTS
6.3 REAGENTS
6.4 OTHERS

7 MOLECULAR DIAGNOSTIC MARKET, BY TECHNOLOGY

7.1 INTRODUCTION
7.2 PCR
7.3 HYBRIDIZATION
7.4 DNA SEQUENCING
7.5 MICROARRAY
7.6 INAAT
7.7 MASS SPECTROMETRY
7.8 TRANSCRIPTION MEDIATED AMPLIFICATION

8 MOLECULAR DIAGNOSTIC MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 INFECTIOUS DISEASE
8.3 ONCOLOGY
8.4 GENETIC TESTS
8.5 PHARMACOGENOMICS
8.6 NEUROLOGICAL DISEASES
8.7 CARDIOVASCULAR DISEASES
8.8 MICROBIOLOGY

9 MOLECULAR DIAGNOSTIC MARKET, BY END-USE

9.1 INTRODUCTION
9.2 HOSPITAL
9.3 LABORATORIES
9.4 OTHERS

10 MOLECULAR DIAGNOSTIC MARKET, BY REGION

10.1 INTRODUCTION

10.2 NORTH AMERICA
10.2.1 BY PRODUCT
10.2.2 BY TECHNOLOGY
10.2.3 BY APPLICATION
10.2.4 BY END-USE
10.2.5 BY COUNTRY
10.2.5.1 U.S.
10.2.5.1.1 By product
10.2.5.1.2 By technology
10.2.5.1.3 By application.
10.2.5.1.4 By end-use
10.2.5.2 CANADA
10.2.5.2.1 By product
10.2.5.2.2 By technology
10.2.5.2.3 By application.
10.2.5.2.4 By end-use
10.2.5.3 MEXICO
10.2.5.3.1 By product
10.2.5.3.2 By technology
10.2.5.3.3 By application.
10.2.5.3.4 By end-use

10.3 EUROPE
10.3.1 BY PRODUCT
10.3.2 BY TECHNOLOGY
10.3.3 BY APPLICATION
10.3.4 BY END-USE
10.3.5 BY COUNTRY
10.3.5.1 GERMANY
10.3.5.1.1 By product
10.3.5.1.2 By technology
10.3.5.1.3 By application.
10.3.5.1.4 By end-use
10.3.5.2 UK
10.3.5.2.1 By product
10.3.5.2.2 By technology
10.3.5.2.3 By application.
10.3.5.2.4 By end-use
10.3.5.3 FRANCE
10.3.5.3.1 By product
10.3.5.3.2 By technology
10.3.5.3.3 By application.
10.3.5.3.4 By end-use
10.3.5.4 ITALY
10.3.5.4.1 By product
10.3.5.4.2 By technology
10.3.5.4.3 By application.
10.3.5.4.4 By end-use
10.3.5.5 SPAIN
10.3.5.5.1 By product
10.3.5.5.2 By technology
10.3.5.5.3 By application.
10.3.5.5.4 By end-use
10.3.5.6 BELGIUM
10.3.5.6.1 By product
10.3.5.6.2 By technology
10.3.5.6.3 By application.
10.3.5.6.4 By end-use
10.3.5.7 SWITZERLAND
10.3.5.7.1 By product
10.3.5.7.2 By technology
10.3.5.7.3 By application.
10.3.5.7.4 By end-use
10.3.5.8 NETHERLANDS
10.3.5.8.1 By product
10.3.5.8.2 By technology
10.3.5.8.3 By application.
10.3.5.8.4 By end-use
10.3.5.9 POLAND
10.3.5.9.1 By product
10.3.5.9.2 By technology
10.3.5.9.3 By application.
10.3.5.9.4 By end-use
10.3.5.10 AUSTRIA
10.3.5.10.1 By product
10.3.5.10.2 By technology
10.3.5.10.3 By application.
10.3.5.10.4 By end-use
10.3.5.11 GREECE
10.3.5.11.1 By product
10.3.5.11.2 By technology
10.3.5.11.3 By application.
10.3.5.11.4 By end-use
10.3.5.12 SWEDEN
10.3.5.12.1 By product
10.3.5.12.2 By technology
10.3.5.12.3 By application.
10.3.5.12.4 By end-use
10.3.5.13 TURKEY
10.3.5.13.1 By product
10.3.5.13.2 By technology
10.3.5.13.3 By application.
10.3.5.13.4 By end-use
10.3.5.14 FINLAND
10.3.5.14.1 By product
10.3.5.14.2 By technology
10.3.5.14.3 By application.
10.3.5.14.4 By end-use

10.4 ASIA PACIFIC
10.4.1 BY PRODUCT
10.4.2 BY TECHNOLOGY
10.4.3 BY APPLICATION
10.4.4 BY END-USE
10.4.5 BY COUNTRY
10.4.5.1 CHINA
10.4.5.1.1 By product
10.4.5.1.2 By technology
10.4.5.1.3 By application.
10.4.5.1.4 By end-use
10.4.5.2 INDIA
10.4.5.2.1 By product
10.4.5.2.2 By technology
10.4.5.2.3 By application.
10.4.5.2.4 By end-use
10.4.5.3 JAPAN
10.4.5.3.1 By product
10.4.5.3.2 By technology
10.4.5.3.3 By application.
10.4.5.3.4 By end-use
10.4.5.4 SRILANKA
10.4.5.4.1 By product
10.4.5.4.2 By technology
10.4.5.4.3 By application.
10.4.5.4.4 By end-use
10.4.5.5 MALAYSIA
10.4.5.5.1 By product
10.4.5.5.2 By technology
10.4.5.5.3 By application.
10.4.5.5.4 By end-use
10.4.5.6 AUSTRALIA
10.4.5.6.1 By product
10.4.5.6.2 By technology
10.4.5.6.3 By application.
10.4.5.6.4 By end-use
10.4.5.7 NEW ZELAND
10.4.5.7.1 By product
10.4.5.7.2 By technology
10.4.5.7.3 By application.
10.4.5.7.4 By end-use
10.4.5.8 THAILAND
10.4.5.8.1 By product
10.4.5.8.2 By technology
10.4.5.8.3 By application.
10.4.5.8.4 By end-use
10.4.5.9 VIETNAM
10.4.5.9.1 By product
10.4.5.9.2 By technology
10.4.5.9.3 By application.
10.4.5.9.4 By end-use
10.4.5.10 SINGAPORE
10.4.5.10.1 By product
10.4.5.10.2 By technology
10.4.5.10.3 By application.
10.4.5.10.4 By end-use

10.5 CENTRAL & SOUTH AMERICA
10.5.1 BY PRODUCT
10.5.2 BY TECHNOLOGY
10.5.3 BY APPLICATION
10.5.4 BY END-USE
10.5.5 BY COUNTRY
10.5.5.1 BRAZIL
10.5.5.1.1 By product
10.5.5.1.2 By technology
10.5.5.1.3 By application.
10.5.5.1.4 By end-use
10.5.5.2 ARGENTINA
10.5.5.2.1 By product
10.5.5.2.2 By technology
10.5.5.2.3 By application.
10.5.5.2.4 By end-use
10.5.5.3 COLUMBIA
10.5.5.3.1 By product
10.5.5.3.2 By technology
10.5.5.3.3 By application.
10.5.5.3.4 By end-use
10.5.5.4 CHILE
10.5.5.4.1 By product
10.5.5.4.2 By technology
10.5.5.4.3 By application.
10.5.5.4.4 By end-use
10.5.5.5 PERU
10.5.5.5.1 By product
10.5.5.5.2 By technology
10.5.5.5.3 By application.
10.5.5.5.4 By end-use

10.6 MIDDLE EAST & AFRICA
10.6.1 BY PRODUCT
10.6.2 BY TECHNOLOGY
10.6.3 BY APPLICATION
10.6.4 BY END-USE
10.6.5 BY COUNTRY
10.6.5.1 SAUDI ARABIA
10.6.5.1.1 By product
10.6.5.1.2 By technology
10.6.5.1.3 By application.
10.6.5.1.4 By end-use
10.6.5.2 UAE
10.6.5.2.1 By product
10.6.5.2.2 By technology
10.6.5.2.3 By application.
10.6.5.2.4 By end-use
10.6.5.3 QATAR
10.6.5.3.1 By product
10.6.5.3.2 By technology
10.6.5.3.3 By application.
10.6.5.3.4 By end-use
10.6.5.4 EGYPT
10.6.5.4.1 By product
10.6.5.4.2 By technology
10.6.5.4.3 By application.
10.6.5.4.4 By end-use

11 END-USE LANDSCAPE (CONSUMER PROFILE)

11.1 NORTH AMERICA
11.2 EUROPE
11.3 ASIA-PACIFIC
11.4 CENTRAL & SOUTH AMERICA
11.5 MIDDLE EAST & AFRICA

12 VENDOR LANDSCAPE (SUPPLIERS/MANUFACTURERS/DISTRIBUTORS)

12.1 NORTH AMERICA
12.2 EUROPE
12.3 ASIA PACIFIC
12.4 REST OF THE WORLD

13 COMPANY PROFILE

13.1 ABBOTT MOLECULAR.
13.1.1 BUSINESS DESCRIPTION
13.1.2 FINANCIAL PERFORMANCE
13.1.3 SWOT ANALYSIS
13.1.4 PRODUCTS AND SERVICES OFFERED
13.1.5 STRATEGIC INITIATIVES

13.2 ALERE, INC.
13.2.1 BUSINESS DESCRIPTION
13.2.2 FINANCIAL PERFORMANCE
13.2.3 SWOT ANALYSIS
13.2.4 PRODUCTS AND SERVICES OFFERED
13.2.5 STRATEGIC INITIATIVES

13.3 QIAGEN N.V.
13.3.1 BUSINESS DESCRIPTION
13.3.2 FINANCIAL PERFORMANCE
13.3.3 SWOT ANALYSIS
13.3.4 PRODUCTS AND SERVICES OFFERED
13.3.5 STRATEGIC INITIATIVES

13.4 ROCHE DIAGNOSTICS
13.4.1 BUSINESS DESCRIPTION
13.4.2 FINANCIAL PERFORMANCE
13.4.3 SWOT ANALYSIS
13.4.4 PRODUCTS AND SERVICES OFFERED
13.4.5 STRATEGIC INITIATIVES

13.5 HOLOGIC, INC
13.5.1 BUSINESS DESCRIPTION
13.5.2 FINANCIAL PERFORMANCE
13.5.3 SWOT ANALYSIS
13.5.4 PRODUCTS AND SERVICES OFFERED
13.5.5 STRATEGIC INITIATIVES

13.6 GRIFOLS
13.6.1 BUSINESS DESCRIPTION
13.6.2 FINANCIAL PERFORMANCE
13.6.3 SWOT ANALYSIS
13.6.4 PRODUCTS AND SERVICES OFFERED
13.6.5 STRATEGIC INITIATIVES

13.7 SIEMENS HEALTHCARE
13.7.1 BUSINESS DESCRIPTION
13.7.2 FINANCIAL PERFORMANCE
13.7.3 SWOT ANALYSIS
13.7.4 PRODUCTS AND SERVICES OFFERED
13.7.5 STRATEGIC INITIATIVES

13.8 BECTON, DICKINSON AND COMPANY
13.8.1 BUSINESS DESCRIPTION
13.8.2 FINANCIAL PERFORMANCE
13.8.3 SWOT ANALYSIS
13.8.4 PRODUCTS AND SERVICES OFFERED
13.8.5 STRATEGIC INITIATIVES

13.9 BECKMAN COULTER INC.
13.9.1 BUSINESS DESCRIPTION
13.9.2 FINANCIAL PERFORMANCE
13.9.3 SWOT ANALYSIS
13.9.4 PRODUCTS AND SERVICES OFFERED
13.9.5 STRATEGIC INITIATIVES

13.10 BIOMÉRIEUX SA
13.10.1 BUSINESS DESCRIPTION
13.10.2 FINANCIAL PERFORMANCE
13.10.3 SWOT ANALYSIS
13.10.4 PRODUCTS AND SERVICES OFFERED
13.10.5 STRATEGIC INITIATIVES

13.11 CEPHEID INC.
13.11.1 BUSINESS DESCRIPTION
13.11.2 FINANCIAL PERFORMANCE
13.11.3 SWOT ANALYSIS
13.11.4 PRODUCTS AND SERVICES OFFERED
13.11.5 STRATEGIC INITIATIVES

13.12 DAKO
13.12.1 BUSINESS DESCRIPTION
13.12.2 FINANCIAL PERFORMANCE
13.12.3 SWOT ANALYSIS
13.12.4 PRODUCTS AND SERVICES OFFERED
13.12.5 STRATEGIC INITIATIVES

13.13 DANAHER CORPORATION
13.13.1 BUSINESS DESCRIPTION
13.13.2 FINANCIAL PERFORMANCE
13.13.3 SWOT ANALYSIS
13.13.4 PRODUCTS AND SERVICES OFFERED
13.13.5 STRATEGIC INITIATIVES

13.14 JOHNSON & JOHNSON SERVICES, IN.
13.14.1 BUSINESS DESCRIPTION
13.14.2 FINANCIAL PERFORMANCE
13.14.3 SWOT ANALYSIS
13.14.4 PRODUCTS AND SERVICES OFFERED
13.14.5 STRATEGIC INITIATIVES

13.15 SYSMEX CORPORATION
13.15.1 BUSINESS DESCRIPTION
13.15.2 FINANCIAL PERFORMANCE
13.15.3 SWOT ANALYSIS
13.15.4 PRODUCTS AND SERVICES OFFERED
13.15.5 STRATEGIC INITIATIVES

The global molecular diagnostic market report has been studied from the year 2016 till 2025. However, the CAGR provided in the market study is from the year 2017 to 2025. The market research method involved three stages: Desk research, Primary survey research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the industry analysis; industry trends; market analysis; market trends; market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply side analysis for the molecular diagnostic market.

Molecular Diagnostic Market

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, VPs, CEOs, COOs, financial consultants, business consultants, strategy consultants, project management consultants, business management consultants, distributors, and end-use product manufacturers.

Molecular Diagnostic Market

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: demand forecasting, market attractiveness, current & future market trends, market share analysis, SWOT analysis of the companies, and customer analytics.

Molecular Diagnostic Market